FDA Designates AlveoGene’s Innovative Gene Therapy for Rare Neonatal Lung Disorder as an Orphan Drug
AlveoGene, a company dedicated to revolutionizing treatments for rare respiratory conditions through inhaled gene therapies, has announced that its novel therapy, AVG-002, has received Orphan Drug Designation from the US Food & Drug Administration (FDA). This recognition is for AVG-002’s […]